Cytokines in immunogenic cell death: Applications for cancer immunotherapy

Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R. Cytokine, 97:123–132, September, 2017.

Paper doi abstract bibtex

Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can eﬃciently eliminate cancer cells, longterm protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most eﬀective ways to protect against cancers that recur and/or metastasize. Activated tumor speciﬁc cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drugresistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the ﬁght against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their eﬀects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore diﬀerent types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.

@article{showalter_cytokines_2017,
	title = {Cytokines in immunogenic cell death: {Applications} for cancer immunotherapy},
	volume = {97},
	issn = {10434666},
	shorttitle = {Cytokines in immunogenic cell death},
	url = {http://linkinghub.elsevier.com/retrieve/pii/S1043466617301539},
	doi = {10.1016/j.cyto.2017.05.024},
	abstract = {Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can eﬃciently eliminate cancer cells, longterm protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most eﬀective ways to protect against cancers that recur and/or metastasize. Activated tumor speciﬁc cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drugresistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the ﬁght against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their eﬀects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore diﬀerent types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.},
	language = {en},
	urldate = {2018-06-29},
	journal = {Cytokine},
	author = {Showalter, Anne and Limaye, Arati and Oyer, Jeremiah L. and Igarashi, Robert and Kittipatarin, Christina and Copik, Alicja J. and Khaled, Annette R.},
	month = sep,
	year = {2017},
	pages = {123--132},
}

Downloads: 0

{"_id":"EGG4Qmb8Tz9bLYr57","bibbaseid":"showalter-limaye-oyer-igarashi-kittipatarin-copik-khaled-cytokinesinimmunogeniccelldeathapplicationsforcancerimmunotherapy-2017","downloads":0,"creationDate":"2019-03-08T19:02:46.431Z","title":"Cytokines in immunogenic cell death: Applications for cancer immunotherapy","author_short":["Showalter, A.","Limaye, A.","Oyer, J. L.","Igarashi, R.","Kittipatarin, C.","Copik, A. J.","Khaled, A. R."],"year":2017,"bibtype":"article","biburl":"https://bibbase.org/zotero/sannpeterson","bibdata":{"bibtype":"article","type":"article","title":"Cytokines in immunogenic cell death: Applications for cancer immunotherapy","volume":"97","issn":"10434666","shorttitle":"Cytokines in immunogenic cell death","url":"http://linkinghub.elsevier.com/retrieve/pii/S1043466617301539","doi":"10.1016/j.cyto.2017.05.024","abstract":"Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can eﬃciently eliminate cancer cells, longterm protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most eﬀective ways to protect against cancers that recur and/or metastasize. Activated tumor speciﬁc cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drugresistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the ﬁght against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their eﬀects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore diﬀerent types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.","language":"en","urldate":"2018-06-29","journal":"Cytokine","author":[{"propositions":[],"lastnames":["Showalter"],"firstnames":["Anne"],"suffixes":[]},{"propositions":[],"lastnames":["Limaye"],"firstnames":["Arati"],"suffixes":[]},{"propositions":[],"lastnames":["Oyer"],"firstnames":["Jeremiah","L."],"suffixes":[]},{"propositions":[],"lastnames":["Igarashi"],"firstnames":["Robert"],"suffixes":[]},{"propositions":[],"lastnames":["Kittipatarin"],"firstnames":["Christina"],"suffixes":[]},{"propositions":[],"lastnames":["Copik"],"firstnames":["Alicja","J."],"suffixes":[]},{"propositions":[],"lastnames":["Khaled"],"firstnames":["Annette","R."],"suffixes":[]}],"month":"September","year":"2017","pages":"123–132","bibtex":"@article{showalter_cytokines_2017,\n\ttitle = {Cytokines in immunogenic cell death: {Applications} for cancer immunotherapy},\n\tvolume = {97},\n\tissn = {10434666},\n\tshorttitle = {Cytokines in immunogenic cell death},\n\turl = {http://linkinghub.elsevier.com/retrieve/pii/S1043466617301539},\n\tdoi = {10.1016/j.cyto.2017.05.024},\n\tabstract = {Despite advances in treatments like chemotherapy and radiotherapy, metastatic cancer remains a leading cause of death for cancer patients. While many chemotherapeutic agents can eﬃciently eliminate cancer cells, longterm protection against cancer is not achieved and many patients experience cancer recurrence. Mobilizing and stimulating the immune system against tumor cells is one of the most eﬀective ways to protect against cancers that recur and/or metastasize. Activated tumor speciﬁc cytotoxic T lymphocytes (CTLs) can seek out and destroy metastatic tumor cells and reduce tumor lesions. Natural Killer (NK) cells are a front-line defense against drugresistant tumors and can provide tumoricidal activity to enhance tumor immune surveillance. Cytokines like IFN-γ or TNF play a crucial role in creating an immunogenic microenvironment and therefore are key players in the ﬁght against metastatic cancer. To this end, a group of anthracyclines or treatments like photodynamic therapy (PDT) exert their eﬀects on cancer cells in a manner that activates the immune system. This process, known as immunogenic cell death (ICD), is characterized by the release of membrane-bound and soluble factors that boost the function of immune cells. This review will explore diﬀerent types of ICD inducers, some in clinical trials, to demonstrate that optimizing the cytokine response brought about by treatments with ICD-inducing agents is central to promoting anti-cancer immunity that provides long-lasting protection against disease recurrence and metastasis.},\n\tlanguage = {en},\n\turldate = {2018-06-29},\n\tjournal = {Cytokine},\n\tauthor = {Showalter, Anne and Limaye, Arati and Oyer, Jeremiah L. and Igarashi, Robert and Kittipatarin, Christina and Copik, Alicja J. and Khaled, Annette R.},\n\tmonth = sep,\n\tyear = {2017},\n\tpages = {123--132},\n}\n\n","author_short":["Showalter, A.","Limaye, A.","Oyer, J. L.","Igarashi, R.","Kittipatarin, C.","Copik, A. J.","Khaled, A. R."],"key":"showalter_cytokines_2017","id":"showalter_cytokines_2017","bibbaseid":"showalter-limaye-oyer-igarashi-kittipatarin-copik-khaled-cytokinesinimmunogeniccelldeathapplicationsforcancerimmunotherapy-2017","role":"author","urls":{"Paper":"http://linkinghub.elsevier.com/retrieve/pii/S1043466617301539"},"metadata":{"authorlinks":{}},"html":""},"search_terms":["cytokines","immunogenic","cell","death","applications","cancer","immunotherapy","showalter","limaye","oyer","igarashi","kittipatarin","copik","khaled"],"keywords":[],"authorIDs":[],"dataSources":["JPAoq8b4ppzXj5XYZ"]}